DE69739956D1 - Calciumaktivierter Kaliumkanal mit zwischenzeitlicher Konduktanz und Verwendungen davon - Google Patents

Calciumaktivierter Kaliumkanal mit zwischenzeitlicher Konduktanz und Verwendungen davon

Info

Publication number
DE69739956D1
DE69739956D1 DE69739956T DE69739956T DE69739956D1 DE 69739956 D1 DE69739956 D1 DE 69739956D1 DE 69739956 T DE69739956 T DE 69739956T DE 69739956 T DE69739956 T DE 69739956T DE 69739956 D1 DE69739956 D1 DE 69739956D1
Authority
DE
Germany
Prior art keywords
potassium channel
activated potassium
calcium
intermediate conductance
calcium activated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69739956T
Other languages
German (de)
English (en)
Inventor
John P Adelman
Christopher P Silvia
James Maylie
Chris T Bond
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ICA GEN Inc
Oregon Health & Science University
Original Assignee
ICA GEN Inc
Oregon Health & Science University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ICA GEN Inc, Oregon Health & Science University filed Critical ICA GEN Inc
Application granted granted Critical
Publication of DE69739956D1 publication Critical patent/DE69739956D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
DE69739956T 1996-09-11 1997-09-10 Calciumaktivierter Kaliumkanal mit zwischenzeitlicher Konduktanz und Verwendungen davon Expired - Lifetime DE69739956D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2645196P 1996-09-11 1996-09-11
US4005297P 1997-03-07 1997-03-07
US4523397P 1997-04-17 1997-04-17

Publications (1)

Publication Number Publication Date
DE69739956D1 true DE69739956D1 (de) 2010-09-16

Family

ID=27362774

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69739956T Expired - Lifetime DE69739956D1 (de) 1996-09-11 1997-09-10 Calciumaktivierter Kaliumkanal mit zwischenzeitlicher Konduktanz und Verwendungen davon
DE69737889T Expired - Lifetime DE69737889T2 (de) 1996-09-11 1997-09-10 Kalzium-aktivierte kaliumkanäle mit niedriger und mittlerer leitfähigkeit und ihre verwendungen.

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69737889T Expired - Lifetime DE69737889T2 (de) 1996-09-11 1997-09-10 Kalzium-aktivierte kaliumkanäle mit niedriger und mittlerer leitfähigkeit und ihre verwendungen.

Country Status (8)

Country Link
US (9) US6797486B2 (enExample)
EP (1) EP0948542B1 (enExample)
JP (5) JP4052525B2 (enExample)
AT (1) ATE366260T1 (enExample)
AU (1) AU726158B2 (enExample)
CA (1) CA2265485C (enExample)
DE (2) DE69739956D1 (enExample)
WO (1) WO1998011139A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1012281B1 (en) * 1997-07-15 2006-11-29 AstraZeneca UK Limited Human leukocyte calcium activated potassium channel polypeptide
US6165719A (en) * 1997-07-15 2000-12-26 The Regents Of The University Of California hKCa3/KCNN3 small conductance calcium activated potassium channel: a diagnostic marker and therapeutic target
AU2001265384A1 (en) 2000-06-06 2001-12-17 Millennium Pharmaceuticals, Inc. 52906, 33408, and 12189, potassium channel family members and uses thereof
EP1345618B1 (de) * 2000-12-28 2005-03-23 Switch Biotech Aktiengesellschaft Chlorzoxazon zur behandlung von psoriasis
US7022480B1 (en) * 2001-10-11 2006-04-04 The Regents Of The University Of California Exons of the hSKCa3/KCNN3 gene
US20050250090A1 (en) * 2003-10-28 2005-11-10 Edward Kaftan Assay systems and methods for detecting molecules that interact with SK2 channels
EP1884774A1 (en) * 2006-08-03 2008-02-06 INSERM (Institut National de la Santé et de la Recherche Medicale) A method for the in vitro screening of anti-cancer compounds that inhibits SK3 activity, and said anti-cancer compounds
CN110378549B (zh) * 2019-05-31 2023-05-23 广东工业大学 一种基于fahp-熵权法的输电杆塔鸟害等级评估方法
CN121057823A (zh) * 2023-04-10 2025-12-02 耶鲁大学 体内修饰神经元以治疗和/或预防肌萎缩性侧索硬化(als)的方法
WO2025175135A1 (en) * 2024-02-15 2025-08-21 Yale University Modifying neurons to treat or prevent parkinson's disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT392957B (de) 1987-08-06 1991-07-25 Technoagrar Consulting Ag Verfahren zur behandlung und entsorgung von gemengen aus feststoffen und fluessigkeiten
US6307030B1 (en) * 1988-04-15 2001-10-23 The University Of North Carolina At Chapel Hill Androgen receptor proteins, recombinant DNA molecules coding for such, and use of such compositions
CA2116280A1 (en) * 1993-03-05 1994-09-06 Marcy E. Macdonald Huntingtin dna, protein and uses thereof
US5519003A (en) 1994-02-01 1996-05-21 Board Of Trustees Of The Leland Stanford Junior University WD-40-derived peptides and uses thereof
US6277978B1 (en) * 1995-12-22 2001-08-21 University Of Utah Research Foundation KVLQT1—a long QT syndrome gene
EP1012281B1 (en) 1997-07-15 2006-11-29 AstraZeneca UK Limited Human leukocyte calcium activated potassium channel polypeptide
US6165719A (en) * 1997-07-15 2000-12-26 The Regents Of The University Of California hKCa3/KCNN3 small conductance calcium activated potassium channel: a diagnostic marker and therapeutic target
WO1999025347A2 (en) 1997-11-14 1999-05-27 Neurosearch A/S Chemical compounds having ion channel blocking activity for the treatment of immune dysfunction

Also Published As

Publication number Publication date
US6828420B2 (en) 2004-12-07
US6828122B2 (en) 2004-12-07
EP0948542B1 (en) 2007-07-04
JP2004024268A (ja) 2004-01-29
DE69737889D1 (de) 2007-08-16
AU4266097A (en) 1998-04-02
JP2006320333A (ja) 2006-11-30
AU726158B2 (en) 2000-11-02
CA2265485A1 (en) 1998-03-19
EP0948542A4 (en) 2004-04-14
US7026451B2 (en) 2006-04-11
DE69737889T2 (de) 2008-03-13
US20020155531A1 (en) 2002-10-24
WO1998011139A1 (en) 1998-03-19
US20020165379A1 (en) 2002-11-07
US20030082684A1 (en) 2003-05-01
US20030082683A1 (en) 2003-05-01
JP4052525B2 (ja) 2008-02-27
US7534869B2 (en) 2009-05-19
US20050214845A1 (en) 2005-09-29
US20030105284A1 (en) 2003-06-05
US6894147B2 (en) 2005-05-17
EP0948542A1 (en) 1999-10-13
CA2265485C (en) 2006-08-01
US6828123B2 (en) 2004-12-07
JP2008092950A (ja) 2008-04-24
US6987169B2 (en) 2006-01-17
JP4052582B2 (ja) 2008-02-27
JP2000514310A (ja) 2000-10-31
US20020192757A1 (en) 2002-12-19
US6692937B2 (en) 2004-02-17
US20030044910A1 (en) 2003-03-06
JP2004065264A (ja) 2004-03-04
US20030040048A1 (en) 2003-02-27
ATE366260T1 (de) 2007-07-15
US6797486B2 (en) 2004-09-28

Similar Documents

Publication Publication Date Title
WO2003072803A3 (en) Nanostructures containing antibody assembly units
ATE218708T1 (de) Elektrochemischer affinitätsassay
BR9910332A (pt) Polipeptìdio, composição, método para purificação de polipeptìdio a partir de uma composição e método para purificação de um anticorpo a partir de uma composição
ATE522609T1 (de) Neurotrophe faktoren
PT1015585E (pt) Homologos de ligandos de tie
DE69939820D1 (de) Internalisierende erbb2 antikörper
EP1379693A4 (en) BIO STICK CODES BASED ON OLIGONUCLEOTIDE-MODIFIED PARTICLES
BE2010C021I2 (enExample)
ES2180899T3 (es) Dihidrato d de olanzapina.
WO2004033631A8 (en) Nucleic acid and polypeptide sequences from lawsonia intracellularis and methods of using
EA200300464A1 (ru) ГУМАНИЗИРОВАННОЕ АНТИТЕЛО ПРОТИВ РЕЦЕПТОРА ЛИМФОТОКСИНА-β (ВАРИАНТЫ), КОМПОЗИЦИЯ, СПОСОБ ЛЕЧЕНИЯ ИЛИ СНИЖЕНИЯ РИСКА РАЗВИТИЯ, ТЯЖЕСТИ ИЛИ ПОСЛЕДСТВИЙ НЕОПЛАЗИИ У ЧЕЛОВЕКА, ВЫДЕЛЕННАЯ НУКЛЕИНОВАЯ КИСЛОТА (ВАРИАНТЫ), КЛЕТКА КЛЕТОЧНОЙ ЛИНИИ
ATE419388T1 (de) Nukleinsäureanreicherung
EP1687283A4 (en) FOR THE DETERMINATION OF FK506 PROCEDURE AND COMPOSITION
DK0955103T3 (da) Rørledningskøretøj med bybass til hastighedsstyring
IL139478A0 (en) Hybrid protein
DE69709561D1 (de) Östrogen-Rezeptor
HUT77049A (hu) Katepszin-02-fehérjék, -nukleinsavak és -ellenanyagok
BR0207933A (pt) Mutantes de interleucina-18, sua produção e uso
ATE366260T1 (de) Kalzium-aktivierte kaliumkanäle mit niedriger und mittlerer leitfähigkeit und ihre verwendungen.
AU7571998A (en) Rapid evaluation of the ratio of biological molecules
DE69725459D1 (de) Substituierte 1,2,3,4-tetrahydro-2-dibenzofuranamine und 2-aminocyclohepta(b)benzofurane
ATE356831T1 (de) Neuer galaninrezeptor
BR0109590A (pt) Mistura de substáncias contendo bisfenol a
PE20399A1 (es) Muteina ob
EP1892252A3 (en) Intermediate conductance, calcium-activated potassium channels and uses thereof